People living with coronary artery disease often face challenges when doctors need to open blocked arteries. When these blockages are in specific sized vessels, doctors must choose the best method to keep the artery open and ensure the heart continues to function properly. This research looks at a specific technique called a sirolimus-eluting balloon (SEB) and compares it to the standard method of using a drug-eluting stent (DES) to treat these blockages.
To conduct this study, researchers enrolled a large group of 3,323 patients who had new blockages in arteries measuring between 2 and 5 millimeters in diameter. The patients were split into two groups. One group received the sirolimus-eluting balloon with a provisional stent, while the other group received a standard drug-eluting stent. The goal was to see if the balloon method was just as safe and effective as the standard stent over a 12-month period.
The primary goal of the study was to measure "target vessel failure." This is a combined measure of serious events like heart-related death, heart attacks in the treated area, or the need for another procedure to fix the same vessel. The results showed that the balloon method was not inferior to the standard stent. In the group using the balloon, 5.3% of patients experienced a failure, while 4.4% of those with the standard stent did. This small difference suggests that both methods performed similarly in terms of major safety and success outcomes over the first year.
However, there was a slight difference in a secondary measure. Patients who received the balloon were slightly more likely to need a follow-up procedure to re-open the vessel (3.3% compared to 2.1% for the stent group). Regarding safety, the researchers reported that the number of blood clots in the area was low and similar for both types of treatments. It is important to note that while the main results were positive for the balloon method, some specific data points were less clear. For example, when researchers looked only at patients who completed every step of the treatment perfectly, the results were not as clearly consistent as the initial broad group. Because this is a single trial with a specific focus on a certain artery size, it does not mean the balloon is the best choice for every type of heart condition.
For patients today, this means that for specific types of coronary artery blockages, the sirolimus-eluting balloon is a viable and comparable alternative to standard stents. Patients and doctors can view it as a comparable option for these specific cases, though the choice will always depend on the individual's specific anatomy and medical history.
